Ridgefield, CT, April 6, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug Application (sNDA) for ...

Boehringer Ingelheim has announced that the new findings published demonstrate that Pradaxa (dabigatran etexilate) is associated with a substantially shorter interruption of oral anticoagulation ...

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...

Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has granted full approval for Praxbind (idarucizumab) for use in patients treated with Pradaxa (dabigatran etexilate mesylate ...

Ridgefield, Conn., November 13, 2017 – Boehringer Ingelheim today announced results from two new analyses of the phase III RE-VERSE AD™ study, which evaluated the safety and efficacy of idarucizumab, ...

Findings from an analysis of four Phase III trials, comparing Pradaxa ® to enoxaparin recently published in Thrombosis Research, support the positive safety profile of Pradaxa ® for the prevention of ...

PRADAXA (dabigatran etexilate) 75mg, 150mg capsules by Boehringer Ingelheim This marks the fourth FDA approval for the anticoagulant. The Food and Drug Administration (FDA) has approved Pradaxa ...

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...

INGELHEIM, Germany--(BUSINESS WIRE)--For Non-US, Non-UK & Non-Canadian Media Only Findings published in Circulation demonstrate that Pradaxa ® (dabigatran etexilate) is associated with a substantially ...

“The RE-VERSE AD study has demonstrated that idarucizumab can reverse the anticoagulant effect of dabigatran within minutes, allowing physicians to quickly initiate emergency interventions for ...